von seoul1 » 04.10.2015, 21:51
Hallo , es gibt eine weitere, echt erfreuliche Neuigkeit zu ACP 196, dem Nachfolgemed für Ibrutinib.
Wie hier jemand mitteilt, aus absolut verlässlicher Quelle, wie er sagt, wird bei der ASH 2015 eine Studie zu ACP 196 vorgestellt, die beim progressionsfreien Überleben eine glatte Linie zeigt, dass hieße, bei allen Patienten hat es angesprochen und wirkt bis heute.
HalI thought I would descend on this thread with some encouraging information on ACP-196. It's a little tidbit that I learned of today regarding an upcoming ASH 2015 paper on ACP-196 that I happened to get a sneak preview of, or at least a preview of one particularly significant chart therein that is. The chart I was shown—and I'm not saying where I saw it, but I state soberly that it was from a more than highly reliable source—was a PFS chart for monotherapy ACP-196 for CLL. Not being able to obtain a copy, allow me to describe what this chart showed. First, as many of you have commonly seen, a PFS (progression free survival) chart typically looks something like an uneven descending staircase, which extends from right to left as a measure of time, and with each lower step representing someone who's luck with the drug has begun to falter, that is, to "progress", at that point in time. They [the charts] typically start from the right with longer flat steps, then as time progresses the steps become shorter and shorter, more skinny steps dropping faster downward. Many of these charts, especially with the older CLL drugs eventually came to a cliff-like last couple steps and then (insert sound of Wile E. Coyote falling into the gorge.) With the newer, more effective drugs, like GA101 (Gazyva), Ibrutinib, etc, the staircase descends (mercifully) much more gradually and in some cases can sort of plateau. (I'm generalizing.) Can you guess what the PFS staircase looked like for the ACP-196 cohort?
...
I'll draw it here as best I can in text:
|—————————————————————————————————————————
| ^ PFS Line ^
|
|
|
|_______________________________________________________________
- Time ->
I realize I'm leaving out some important units here such as cohort size, timespan, and any particulars about the risk factors of individuals in the cohort, but I was only show the chart briefly on said reliable source's smart phone. Let me however provide you with this direct quote from this individual (and I hope he pardons me for doing so), "Once the ASH abstracts are released and people can see the data, ACP-196 is going to make ibrutinib look like child's play."
I apologize that I cannot provide a link to the actual source article that I was shown. I believe it is safe to assume that it will be published sometime soon, however.
Thanks for allowing me to fill your minds with hearsay, but mark my words that what I saw was authentic and my source unsqueezabley solid.
.
Ich denke, der Bericht zu ASH 2015s ollte bald im Netz sein.
Gruss Seoul
Hallo , es gibt eine weitere, echt erfreuliche Neuigkeit zu ACP 196, dem Nachfolgemed für Ibrutinib.
Wie hier jemand mitteilt, aus absolut verlässlicher Quelle, wie er sagt, wird bei der ASH 2015 eine Studie zu ACP 196 vorgestellt, die beim progressionsfreien Überleben eine glatte Linie zeigt, dass hieße, bei allen Patienten hat es angesprochen und wirkt bis heute.
HalI thought I would descend on this thread with some encouraging information on ACP-196. It's a little tidbit that I learned of today regarding an upcoming ASH 2015 paper on ACP-196 that I happened to get a sneak preview of, or at least a preview of one particularly significant chart therein that is. The chart I was shown—and I'm not saying where I saw it, but I state soberly that it was from a more than highly reliable source—was a PFS chart for monotherapy ACP-196 for CLL. Not being able to obtain a copy, allow me to describe what this chart showed. First, as many of you have commonly seen, a PFS (progression free survival) chart typically looks something like an uneven descending staircase, which extends from right to left as a measure of time, and with each lower step representing someone who's luck with the drug has begun to falter, that is, to "progress", at that point in time. They [the charts] typically start from the right with longer flat steps, then as time progresses the steps become shorter and shorter, more skinny steps dropping faster downward. Many of these charts, especially with the older CLL drugs eventually came to a cliff-like last couple steps and then (insert sound of Wile E. Coyote falling into the gorge.) With the newer, more effective drugs, like GA101 (Gazyva), Ibrutinib, etc, the staircase descends (mercifully) much more gradually and in some cases can sort of plateau. (I'm generalizing.) Can you guess what the PFS staircase looked like for the ACP-196 cohort?
...
I'll draw it here as best I can in text:
|—————————————————————————————————————————
| ^ PFS Line ^
|
|
|
|_______________________________________________________________
- Time ->
I realize I'm leaving out some important units here such as cohort size, timespan, and any particulars about the risk factors of individuals in the cohort, but I was only show the chart briefly on said reliable source's smart phone. Let me however provide you with this direct quote from this individual (and I hope he pardons me for doing so), "Once the ASH abstracts are released and people can see the data, ACP-196 is going to make ibrutinib look like child's play."
I apologize that I cannot provide a link to the actual source article that I was shown. I believe it is safe to assume that it will be published sometime soon, however.
Thanks for allowing me to fill your minds with hearsay, but mark my words that what I saw was authentic and my source unsqueezabley solid.
.
Ich denke, der Bericht zu ASH 2015s ollte bald im Netz sein.
Gruss Seoul
